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Introduction 
Reversible posterior leukoencephalopathy 
syndrome (RPLS) was a term first used by Hinchey 
et al [1] in 1996 to describe a distinct 
clinico-radiological entity comprising headache, 
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Abstract  
Introduction: Reversible posterior leukoencephalopathy syndrome (RPLS) is characterized clinically by headache, abnormalities 
of mental status and visual perception, and seizures. Despite its diverse causes, common precipitating factors are defined as 
abrupt elevations of blood pressure, renal decompensation, fluid retention, and immunosuppressive therapy. 
Presentation of Case: We report a case of a child, aged five and half years old, having symptomatic FMF confirmed by genetic 
studies, who developed Hodgkin lymphoma while on colchicine therapy. The association between MEFV gene mutations, the 
gene responsible for familial Mediterranean fever (FMF), and hematolymphoid neoplasms has been recently suggested. Initiation 
of chemotherapy was complicated by development of RPLS. After initial good response to chemotherapy, the patient developed 
progressive Hodgkin disease with evidence of secondary amyloidosis despite regular colchicine therapy. 
Conclusion: The causes of RPLS in our case could be multifactorial, that could stem from the abrupt elevation of blood pressure, 
high-dose chemotherapy, Hodgkin disease or the FMF.   
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seizures, visual disturbance, and altered mental 
function associated with symmetrical posterior 
cerebral white matter oedema [2]. RPLS is an 
uncommon but distinctive clinicoradiological entity 
comprising of headache, seizures, visual disturbance, 
and altered mental function. RPLS has been 
previously reported in association with 
immunosuppressive therapy [3, 4]. Previous study 
described RPLS in FMF patients during attacks 
associated with hypertension [5].  
Familial Mediterranean fever (FMF) is an 
autosomal recessive disorder characterized by 
recurrent attacks of fever and serositis affecting 
mainly Mediterranean populations (Jews, Armenians, 
Arabs, and Turks). Most patients begin to suffer 
during childhood, 60% before 10 years of age and 
90% before the age of 20 years. The disease is 
characterized mainly by fever with abdominal pain 
and/or arthritis [6]. FMF is caused by mutations in 
MEFV gene, which encodes pyrin and results in 
uncontrolled inflammation [7]. The prevalence of 
Hodgkin lymphoma in patients with FMF is rare and 
its association is equivocal [8].  
Specific magnetic resonance (MR) techniques, 
such as FLAIR (fluid attenuated inversion recovery) 
and DWI (diffusion weighted images) sequences, 
have improved the ability to detect 
subcortical/cortical lesions and helped to clarify the 
underlying pathophysiological mechanism of 
cerebrovascular involvement, which results 
important for an appropriate therapeutic decision [9]. 
We report the case of a child with FMF and Hodgkin 
lymphoma, mixed cellularity subtype, complicated 
with post-chemotherapy RPLS. 
 
Case Presentation 
   A five and half years old  male patient, second in 
order of birth of first cousin parents, diagnosed at the 
age of 4 years as a case of familial mediterranean fever 
(FMF). The diagnosis was suggested by recurrent 
attacks of fever, arthralgia, and infrequent attacks of 
abdominal pain without organomegaly, and proved by 
molecular genetic analysis of having combined 
heterozygous state for M694V and M694I mutations in 
MEFV gene. The patient was on regular colchicine 
therapy (1 mg /day) and had partial clinical response. 
While on treatment for eight months, he developed 
progressive abdominal enlargement, recurrent fever, 
and his clinical condition was re-evaluated.  
By examination, the patient looked toxic and ill, his 
weight was 20 kg (75
th
 centile for age), height was 
115cm (95
th
 centiles for age), temperature was 39°C, 
blood pressure was 100/70 mm Hg (90
th
 /75
th
 centile 
for age).  Abdominal examination revealed 
hepatomegaly, the right lobe of the liver was palpable 
4cm below the costal margin and the span was 12cm, 
the spleen was palpable 2 cm along its long axis, and 
he had generalized lymphadenopathy.   
    Investigations revealed normocytic normochromic 
anemia, low serum iron and normal total iron binding 
capacity, repeatedly elevated ESR and CRP, elevated 
cytomegalovirus IgG titre while other viral markers  
were negative, normal kidney and liver function tests, 
and normal serum amyloid A. Results were negative 
for lupus anticoagulant, anti-DNA and antinuclear 
antibodies, and anticardiolipin IgM and IgG. 
    CT scan revealed multiple enlarged mediastinal, 
pretreacheal, retrocaval, right paratracheal, azygo-
oesphageal, subcarinal and hilar enlarged lymph nodes, 
the largest measuring 1.5x2.5 cm as well as multiple 
enlarged lymph nodes in the portahepatis, 
peripancreatic, celiac and paraaortic regions, the 
largest measuring 2.5 cm in diameter, and  multiple 
bilateral confluent infiltrative lung lesions. The liver 
and the spleen were enlarged showing multiple 
heterogenous hypodense areas.  
   Echocardiography was normal. Bone marrow 
aspirate and biopsy were negative for neoplastic 
infiltration and/or fibrosis.  CT-guided true cut biopsy 
from the abdominal lymph nodes, examined 
pathologically was reported as Hodgkin lymphoma, 
mixed cellularity subtype. The tumour cells were 
positive for CD 15 and CD 30 and negative for CD20.  
    The patient was diagnosed as Hodgkin lymphoma 
stage IVB, and the patient was scheduled to receive 8 
ABVD cycles (Doxorubicin, Bleomycin, Vinblastine 
and Dacarbazine given on days 0 and 14 of each cycle) 
[10].  
    Seven days after the 1
st
 chemotherapy session 
(ABVD 1a) had been given, the patient developed 
right sided focal convulsions with secondary 
generalization. One day following the onset of 
convulsions, he experienced sudden transient bilateral 
blindness that lasted few minutes. He developed acute 
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hypertension (170/120 mm Hg), fundus examination 
revealed bilateral pale optic disc. Serum electrolytes, 
CSF examination and CT brain were normal. 
    MRI brain (Figure 1) revealed moderate sized 
lesions mostly cortical and subcortical in left 
temporoparietally and to less extent occipital regions 
with bright signal on FLAIR and T2-Weighted MRI 
(T2-WI). It also showed gyral like pattern of post 
contrast enhancement. There was a mid pontine small 
lesion which was identified with high signal on FLAIR 
and T2-WI MRI, while low signal on T1-WI MRI and 
which was not enchancing on the enclosed images.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 MRI brain: Moderate sized lesions mostly cortical and subcortical in temporo-parietal and 
occipital lobes bilaterally 
 
    After four days, MRI brain was repeated (Figure 2), showed progressive course, particularly as regards the 
occipital lobes bilaterally, with new several bilateral cerebral hemispheric moderate sized zones of signal 
abnormality mostly cortical and subcortical but also with deep white matter involvement. MR Spectroscopy 
(Figure 3) showed inflammatory nature of the lesions. Magnetic resonance perfusion study (Figure 4) revealed 
that the lesions showed hypoperfusion, whereas MRA was normal. Renal ultrasonography and duplex were 
normal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Follow up MRI brain: Progressive course, particularly the occipital lobes bilaterally, with new several 
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bilateral cerebral hemispheric of signal abnormality 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
Figure 3 MR Spectroscopy: Inflammatory nature of the lesions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Magnetic resonance perfusion studies: the lesions showed hypoperfusion. 
 
    
The patient was initially diagnosed as possible 
multiple subacute infarctions versus viral encephalitis. 
Accordingly, he was started anticonvulsant therapy 
(intravenous phenytoin), low molecular weight 
heparin, intravenous acyclovir and immunoglobulin 
therapy. Blood pressure was controlled by oral 
antihypertensive drugs in the form of ACE inhibitor 
(captopril 12.5 mg /8h), calcium channel blocker 
(amlodipine 50mg/day) and diuretic (furosemide 0.5 
mg tab in the morning), this treatment had been 
gradually withdrawn after stabilization and patient was 
maintained only on amlodipine).  Heparin was stopped 
after a few days.  After 5 days, the patient markedly 
improved with control of convulsions and 
hypertension.  
After stabilization, the patient resumed ABVD 
chemotherapy cycle Ib on day 20 with 6 days delay. 
MRI brain was repeated six months later and was 
normal; suggesting the diagnosis of reversible 
posterior leukoencephalopathy syndrome (RPLS). 
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    After completion of chemotherapy, whole body 
PET/CT was done and revealed residual 
pathological metabolically active single focal lesion 
in the spleen and low grade active focal foci in mid-
abdomen consistent with suspected residual activity in 
celiac lymph nodes. Whether these lesions were related 
to Hodgkin disease or FMF itself or related to the 
developing amyloidosis could not be decided as no 
sites were available for biopsy. Splenomegaly has been 
reported in as many as 57% of the cases of FMF in 
various series and lymphadenopathy, with biopsy of 
the glands, showing non-specific hyperplasia [11].  On 
the other hand, PET positive lesions simulating 
malignancy were previously described in patients with 
amyloidosis in various sites including the lungs and 
bones [11, 12].  Because malignancy could not be 
excluded, the possibility of residual Hodgkin disease 
was considered.  
    Unfortunately, the patient was refractory to initial 
chemotherapy.  Salvage therapy was started as DHAP 
(cytosine arabinoside-cisplatin-dexamethasone) 
protocol [13], and the patient was scheduled for 
autologus bone marrow transplantation as he had no 
HLA matched donor. While on salvage therapy, the 
disease progressed rapidly with numerous pulmonary, 
osseous and nodal (pretracheal, retrocaval, subcarinal, 
paraaortic) lesions and biopsy confirmed relapsed 
Hodgkin disease. Serum Amyloid A protein was 
assessed for suspected amyloidosis, and its value was 
high for the reference age range (410 mg/l). Bone 
biopsy was done from the active lesion in the femur, 
pathology and immunohistochemistry confirmed 
Hodgkin lymphoma relapse, unfortunately the patient 
died while on salvage therapy.   
 
Discussion 
Reversible posterior leukoencephalopathy syndrome 
(RPLS) is an uncommon but distinctive 
clinicoradiological entity characterized by the 
development of headache, seizures, visual disturbance, 
and altered mental function, in association with 
posterior cerebral white matter oedema. With 
appropriate management, RPLS is reversible in the 
majority of cases [14]. Previous reported associations 
of RPLS include hypertension, eclampsia, renal 
failure, malignancy, use of immunosuppressive drugs, 
systemic lupus erythematosus, FMF [4, 15].  Typically,   
RPLS lesions in MRI occur predominantly in the 
posterior white matter of subcortical region and some 
involvement of the cortex can also exist [16].  
    Familial Mediterranean fever (FMF) is caused by 
mutations in the MEFV gene, which encodes for the 
pyrin protein, involved in the regulation of apoptosis 
and inflammation. Its N-terminal pyrin domain 
regulates caspase-1 activation and consequently, 
interleukin-1β production. Mutations interfere with the 
role of the pyrin domain, allowing an uninterrupted 
inflammatory cascade [6, 7]. So far, more than 60 
FMF-associated mutations have been detected [3].  
Molecular genetic testing revealed our patient to 
have combined heterozygosity for M694V and 
M694I mutation in MEFV gene; both have been 
described as the commonest mutations in Egyptian 
FMF patients [17]. A previous study [6] reported 
that M694I and A744S mutations were specific to 
Arab populations, and although M694V mutation is 
the most frequent mutation in various ethnic groups, 
it is less common among Arabs and, when present, 
occurs almost only in heterozygous form.           
    The association between FMF and malignancy 
has been under investigation. A recent study [8]   
determined the rate of the five most common MEFV 
gene mutations in 46 patients with hematolymphoid 
neoplasm, and found a high frequency of carriers in 
patients with multiple myeloma (60%), acute 
lymphocytic leukemia (33.3%), least in non-
Hodgkin lymphoma (5%), and no MEFV gene 
mutations in patients with Hodgkin lymphoma. The 
prevalence of Hodgkin lymphoma in patients with 
FMF is rare and its association is equivocal [8]. 
Strong heterozygous mutations such as M694V and 
M680I were predominating in their patients with 
hematolymphoid neoplasm. Similarly, high 
prevalence of MEFV gene mutations in patients 
with myeloid neoplasms has been recently described 
[18]. 
    Our patient, 6 days after receiving the 1st course 
of ABVD, developed convulsions and sudden onset 
of blindness. CNS infection was excluded by the 
normal CSF. CNS involvement of Hodgkin disease 
is reported to be rare. Gerstner et al., 2008 [19] 
stated that Hodgkin lymphoma, unlike non-Hodgkin 
lymphoma, rarely involves the central nervous 
system with the incidence reported as 0.2% to 0.5% 
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of all HL cases. So, the possibility of CNS disease 
was a remote diagnosis. 
    CNS disease developing in FMF patient has been 
described with three possible etiologies: 
demyelinating lesions and cerebrovascular disease 
being the most common [20], however Reversible 
posterior leukoencephalopathy syndrome (RPLS) 
has been rarely described in FMF especially in 
association with hypertension [5]. 
Neuroimaging of RPLS is typically associated 
with high signal intensity on T2-WI predominantly 
in the posterior regions, which is caused by 
subcortical white matter vasogenic edema [21]. The 
parietal and occipital lobes are most commonly 
affected, followed by the frontal lobes, the inferior 
temporal-occipital junction, and the cerebellum [22]. 
MR diffusion-WI was instrumental in establishing 
and consistently demonstrating that the areas of 
abnormality represent vasogenic edema [23, 24].  
Complete reversibility is generally regarded as a 
defining feature of RPLS. The ideal timing of 
repeated brain imaging to document recovery is 
unclear and resolution of RPLS neuroimaging 
abnormalities probably occurs in the range of 
several days to weeks [25]. Focal areas of restricted 
diffusion (likely representing infarction or tissue 
injury with cytotoxic edema) are uncommon 
(11%–26%) and may be associated with an adverse 
outcome [26]. Hemorrhage (focal hematoma, 
isolated sulcal/subarachnoid blood, or protein) is 
seen in approximately 15% of patients [23, 27].   
The typical clinical picture, the MRI 
abnormalities, MR Spectroscopy (minimal increase 
of choline, mild to moderate increase of 
myoinositol, glutamine, aminoacid, lipid and lactate 
and reduction of normal neuronal marker NAA) and 
the reversibility of the neurological manifestations 
favoured the diagnosis of Reversible posterior 
leukoencephalopathy syndrome (RPLS) which 
could be explained in our case by the sudden 
elevation of blood pressure, the high dose 
chemotherapy given, the underground FMF disease 
and the developed Hodgkin disease. Previous 
studies describe RPLS in FMF patient [15, 5].   
No single chemotherapeutic agent or therapeutic 
regimen has been identified to date as being 
consistently associated with RPLS. Implicated drugs 
have included single-agent cisplatin or cytarabine, 
as well as combinations of adriamycin, 
cyclophosphamide, vincristine, corticosteroids [28] 
and others [4].  
One constant feature in the reported cases of 
RPLS complicating cytotoxic chemotherapy is the 
presence of systemic hypertension [2]. This 
happened with our patient who developed systemic 
hypertension with the onset of neurological signs.  
Once, the blood pressure of the patient was 
controlled, the condition resolved with no residual 
neurological deficit. This is consistent with previous 
reports [3] that stated that in the majority of cases, 
RPLS is fully reversible within a period of days to 
weeks, with removal of the inciting factor and 
control of the blood pressure. Therapeutic strategy 
depends on the cause of PRES and clinical picture.  
Most important are blood pressure regulation, 
control of epileptic attacks, anti-oedema therapy [29] 
and correct any electrolytes imbalance [2]. 
   In this child with FMF on colchicine therapy, the 
progression of amyloidosis was accelerated by the 
co-development of Hodgkin disease, also known to 
predispose to amyloidosis [7, 12].  Renal 
impairment was one of the complications of FMF in 
this patient, making the use of renotoxic 
chemotherapy hazardous. The diagnosis can only be 
confirmed by demonstrating the presence of tissue 
amyloid deposits. Traditionally this required 
histology but the recent introduction of labelled 
serum amyloid P component scintigraphy is a 
specific alternative that provides a quantitative 
macroscopic whole body survey of amyloid deposits 
[30]. 
 
Conclusion 
 
RPLS may be an under-appreciated complication of 
cytotoxic therapy; early diagnosis requires a high 
clinical index of suspicion, appreciation that initial 
neurological deficits are variable and often subtle, 
and timely evaluation of cerebral white matter with 
neuroimaging.  So, meticulous attention is paid to 
changes in weight and blood pressure in any patient 
who receives a combination chemotherapy regimen. 
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